CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
2.0mg of ALG-1001 +1 moredrug
Likely dose
2.0mg of ALG-1001from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02153476
NCT02153476Phase 2Completed
CompareCT.gov

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

Allegro Ophthalmics, LLC·interventional·Posted Jun 3, 2014·Updated Dec 19, 2018

In Brief

A Phase 2 clinical trial evaluating 2.0mg of ALG-1001 and Balanced Salt Solution for Symptomatic Focal Vitreomacular Adhesion. Completed, enrolled 45 participants across 5 sites.

Detailed Summary

Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Focal Vitreomacular Adhesion
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 3, 2014
Enrollment StartFeb 1, 2014
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.1 years ago

Interventions

2.0mg of ALG-1001drug

Balanced Salt Solutiondrug